RxDoctor Payments Data

Caroline Rezk

Physician Assistant · Ripon, CANPI 1316693088

Payments from drug & device makers

$1,282in general payments, 2019–2025

Across 49 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$318
  • AstraZeneca$283
  • Lilly USA, LLC$187
  • Novo Nordisk$102
  • AbbVie$70
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • plus $264 from 9 others

What the payments were for

  • Food & beverage$1,282100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,282 in reported general payments places this provider in the 75th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$33,873
Medicare patients
199
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$7,109
XareltoRivaroxaban12$6,595
Estradiol17$841
Atorvastatin Calcium36$477
Levothyroxine Sodium47$460
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$410
Escitalopram Oxalate22$308
Simvastatin22$229
Omeprazole11$224
Metoprolol Tartrate12$192
Metformin Hcl23$165
Sertraline Hcl16$148
Azithromycin36$147
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$146
Lisinopril23$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20$6,59512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Ripon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →